Low-dose radiotherapy as a chemo-potentiator of a chemotherapy regimen with pemetrexed for recurrent non-small-cell lung cancer: a prospective phase II study.

Vincenzo Valentini, Stefano Margaritora, Mario Balducci, Anna Rita Larici, Maria Lucia Calcagni, Giovanna Mantini, Bruno Meduri, Francesco Micciche', Luigia Nardone, Fiorenza De Rose, Alfredo Cesario, Fabio Maggi, Pierluigi Granone

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

Low-dose radiotherapy (LDR) (<50 cGy) induces enhanced cell killing in vitro via the hyper-radiation sensitivity phenomenon. Aim of this study was to evaluate the safety and efficacy of a palliative regimen combining pemetrexed and LDR (as a chemopotentiator) on patients affected by recurrent non-small-cell lung cancer (NSCLC). METHODS AND MATERIALS: Eligible patients had an ECOG performance status ≤2, one prior chemotherapy regimen for advanced NSCLC, adequate organ function, measurable lesions. Patients received pemetrexed (500 mg/m(2) IV) and concurrent LDR (40 cGy bid on days 1 and 2) delivered to target pulmonary or metastatic disease. This cycle was repeated fourfold every 21 days. The accrual was determined by the single proportion powered analysis (α=0.05, power=0.8) with H0 ("bad" response probability, 9% according to literature) and H1 ("good" response probability, 35% ongoing study); 19 is the number required. RESULTS: Nineteen patients with stage III and IV disease were enrolled. Only one patient experienced neutropenia grade 4. All patients are evaluable for clinical response of irradiated lesion: overall response rate was 42%. CONCLUSIONS: Low-dose radiotherapy combined with pemetrexed has a similar toxicity profile to chemotherapy alone. The response rate of this novel approach is encouraging, since it was higher than what was reported for pemetrexed alone (42% versus 9.1%). Additional scientific investigation of this new treatment paradigm is warranted.
Lingua originaleEnglish
pagine (da-a)161-166
Numero di pagine5
RivistaRadiotherapy and Oncology
Stato di pubblicazionePubblicato - 2012

Keywords

  • nsclc
  • radiotherapy

Fingerprint Entra nei temi di ricerca di 'Low-dose radiotherapy as a chemo-potentiator of a chemotherapy regimen with pemetrexed for recurrent non-small-cell lung cancer: a prospective phase II study.'. Insieme formano una fingerprint unica.

Cita questo